

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(218) CK-MB mass					11							9	9	100%
Samples and groups	[µg/L]													
Sample A1		10,2	1,2	12	11							9	9	100%
(60) Roche		10,4	0,96	9,2	5	0	CVPG	10,2	0,54	27%	7,44	13	5	
Other					6	0						4	4	
								1x 1, 2x 12, 1x 61, 1x 149, 1x 179						
Sample B1		42,9	5,0	12	11							9	9	100%
(60) Roche		41,6	3,1	7,4	5	0	CVPG	41,1	2,2	27%	30	52,2	5	
Other					6	0						4	4	
								1x 1, 2x 12, 1x 61, 1x 149, 1x 179						
(441) Myoglobin					22							19	18	95%
Samples and groups	[µg/L]													
Sample A1		89,2	14	15	22							19	18	95%
(60) Roche		89,9	3,7	4,1	11	0	CVPG	90,4	1,3	22%	70,5	111	11	
Other					11	0						8	8	
								3x 1, 2x 12, 1x 54, 2x 58, 1x 149, 1x 178, 1x 179						
Sample B1		233	41	17	22							19	18	95%
(60) Roche		228	14	6,0	11	0	CVPG	228	3,6	22%	177	279	11	
Other					11	0						8	8	
								3x 1, 2x 12, 1x 54, 2x 58, 1x 149, 1x 178, 1x 179						
(442) Troponin I					18							17	16	94%
Samples and groups	[ng/L]													
Sample A1		52,7	39	74	18							17	16	94%
(839) Beckman Coulter UniCel DxI 600, 800		26,3	4,1	16	8	0	CVPG	25,4	0,89	27%	18,5	32,3	8	
Other					10	0						9	9	
								1x 804, 2x 815, 4x 821, 2x 849, 1x 856						
Sample B1		119	95	80	18							17	17	100%
(839) Beckman Coulter UniCel DxI 600, 800		55,5	7,5	14	8	0	CVPG	52,7	1,6	27%	38,4	67	8	
Other					10	0						9	9	
								1x 804, 2x 815, 4x 821, 2x 849, 1x 856						
(443) Troponin T					27							27	27	100%
Samples and groups	[ng/L]													
Sample A1		87,1	5,2	5,9	27							27	27	100%
(2) Immunochemical methods (hs); (60) Roche		87,4	4,8	5,5	26	0	CVPG	88,9	1,0	22%	69,3	109	26	
Other					1	0						1	1	
								1x 4/61						
Sample B1		143	7,0	4,9	27							27	27	100%
(2) Immunochemical methods (hs); (60) Roche		143	6,6	4,6	26	0	CVPG	145	1,7	22%	113	177	26	
Other					1	0						1	1	
								1x 4/61						
(444) Homocysteine					22							16	15	94%
Samples and groups	[µmol/L]													
Sample A1		9,51	1,3	13	22							16	15	94%
(109) Alere / Axis-Shield		9,46	0,91	9,6	10	0	CVPG	9,64	0,49	26%	7,13	12,2	10	
Other					12	0						6	6	
								3x 1, 1x 29, 2x 58, 1x 60, 2x 75, 1x 149, 1x 179, 1x 999						
Sample B1		9,54	1,4	14	22							16	15	94%
(109) Alere / Axis-Shield		9,47	0,81	8,6	10	0	CVPG	9,63	0,47	26%	7,12	12,2	10	
Other					12	0						6	6	
								3x 1, 1x 29, 2x 58, 1x 60, 2x 75, 1x 149, 1x 179, 1x 999						
(447) NT-proBNP					39							36	36	100%
Samples and groups	[ng/L]													
Sample A1		254	29	12	39							36	36	100%
(60) Roche		252	16	6,3	27	0	CVPG	248	4,0	27%	181	315	27	
Other					12	0						9	9	
								4x 1, 1x 15, 4x 54, 2x 61, 1x 149						
Sample B1		626	91	15	39							36	36	100%
(60) Roche		613	46	7,5	27	0	CVPG	597	9,4	27%	435	759	27	
Other					12	0						9	9	
								4x 1, 1x 15, 4x 54, 2x 61, 1x 149						

Test	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						
							AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}
Set 2													
(449) BNP	[ng/L]				4						3	2	67%
Samples and groups													
Sample A2		63,4	30	48	4						3	3	100%
Other					4	0					3		
						3x 1, 1x 179							
Sample B2		57,4	19	33	4						3	2	67%
Other					4	0					3		
						3x 1, 1x 179							
st_kn_p							End of report						Printed: 27.08.2019